Publications by authors named "Ruolan Xia"

Claim this Profile
D
Dual MNK/VEGFR2 Inhibitor JDB153 Enhances Immunotherapeutic Efficiency and Chemosensitivity in Lung Cancer.
Maosen Xu, Li Xu, Tao Zhang, Xue Li, Ziqi Zhang, Ruolan Xia, Xiawei Wei

MedComm (2020)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort.
Ruolan Xia, Yanying Li, Ling Yang, Meijuan Huang

Cancer Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Game-based learning in medical education.
Maosen Xu, Yong Luo, Yu Zhang, Ruolan Xia, Hong Qian

Front Public Health· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of Hedgehog and Notch signaling pathway in cancer.
Ruolan Xia, Maosen Xu, Jing Yang, Xuelei Ma

Mol Biomed· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the tumor stroma for cancer therapy.
Maosen Xu, Tao Zhang, Ruolan Xia, Yuquan Wei, Xiawei Wei

Mol Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, Treatment, and Outcome of Pancreatic Squamous Cell Carcinoma and Pancreatic Adenocarcinoma: A Propensity Score-Matching Analysis Based on SEER-Database.
Yuqing Wang, Yuwen Zhou, Yueyun Chen, Ruolan Xia, Jiyan Liu

Technol Cancer Res Treat· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.
Yu-Wen Zhou, Qian Xu, Yan Wang, Ruo-Lan Xia, Ji-Yan Liu

Int J Ophthalmol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Ruolan Xia, Yuan Cheng, Xuejiao Han, Yuquan Wei, Xiawei Wei

Front Mol Biosci· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.
Ke Cheng, Yuqing Wang, Yuwen Zhou, Ruolan Xia, Liansha Tang

Clin Med Insights Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.
Maosen Xu, Yang Wang, Ruolan Xia, Yuquan Wei, Xiawei Wei

Cell Prolif· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: A propensity score matching analysis based on the SEER database.
Yu-Wen Zhou, Ruo-Lan Xia, Yue-Yun Chen, Xue-Lei Ma, Ji-Yan Liu

Eur J Surg Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments.
Ruolan Xia, Yuwen Zhou, Yuqing Wang, Jiaming Yuan, Xuelei Ma

Front Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
Yuwen Zhou, Ruolan Xia, Huilang Xiao, Dan Pu, Yixiu Long

Int Immunopharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis